

BEST AVAILABLE COPY

Rec'd PCT/PTO 08 JUN 2005

FAX

BEST AVAILABLE COPY



GlaxoSmithKline

To Mail Stop PCT, Attn: Lamont M. Hunter

Company USPTO

Fax 703-305-3230

From Marjorie J. Pfeiffer

Tel 1-919-483-9038; Facsimile: 1-919-483-7988

E-mail marjorie.j.pfeiffer@gsk.com

Date June 8, 2005

Pages including cover 5

Subject Request for Corrected Filing Receipt

GlaxoSmithKline
PO Box 13398
Five Moore Drive
Research Triangle Park
North Carolina 27709

Tel: 919 483 2100
www.gsk.com

Re: Application of Martin Alistair HAYES et al.
Serial No.: 10/509,519; Int'l. Appl. No.: PCT/EP03/03343
Title: *Process for the Preparation of Morpholine
Derivatives and Intermediates Therefore*
Attorney Docket No. PG4792USw

Attached is:

1. Request for Corrected Filing Receipt;
2. Copy of Official Filing Receipt
3. Copy of PCT publication cover sheet (Int'l. Appl. No. PCT/EP03/03343)

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

Atty. Dkt. No. PG4792USw

BEST AVAILABLE COPY

FILE COPY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Martin Alistair HAYES et al.

Serial No.: 10/509,519

Unit: 1614

Filed: May 2, 2005

Examiner: To be assigned

For: *Process for the Preparation of
Morpholine Derivatives and
Intermediates Therefore*Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR CORRECTED FILING RECEIPT

1. Attached is a copy of the official filing receipt received from the PTO in the above application for which issuance of a corrected filing receipt is respectfully requested. Also attached, for your reference, is a copy of the PCT publication cover sheet for International Application No. PCT/EP03/03343.
2. There is an error with respect to the following data, which is:

☒ incorrectly entered

and/or

☐ omitted.

- | Error in | Correct data |
|--|--|
| 1. <input type="checkbox"/> Applicant's name | 1. |
| 2. <input type="checkbox"/> Applicant's address | 2. |
| 3. <input type="checkbox"/> Title | 3. |
| 4. <input type="checkbox"/> Filing date | 4. |
| 5. <input type="checkbox"/> Serial Number | 5. |
| 6. <input type="checkbox"/> Foreign/PCT Application Re: | 6. |
| 7. <input checked="" type="checkbox"/> Other: Foreign Applications | 7. United Kingdom 0207450.8 03/28/2002 |

Date: June 8, 2005

GlaxoSmithKline

Five Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709

Phone: 919-483-8022

Fax: 919-483-7988



James P. Riek

Registration No.: 39,009

CERTIFICATE OF MAILING (37 CFR 1.8)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being facsimile transmitted or deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: M/S XXX, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Date: June 8, 2005


MARJORIE J. PFEIFFER

BEST AVAILABLE COPY

COPIED TO THE UK



UNITED STATES PATENT AND TRADEMARK OFFICE

 UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/509,519	05/02/2005	1614	920 + 130 = 1050	PG4792USw		5	1

CONFIRMATION NO. 5682

23347

 DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY
 GLAXOSMITHKLINE
 FIVE MOORE DR., PO BOX 13398
 RESEARCH TRIANGLE PARK, NC 27709-3398

FILING RECEIPT



OC000000016059228

JUN 01 2005

Date Mailed: 05/20/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

 Martin Alistair Hayes, Stevenage, GBN, UNITED KINGDOM;
 Gail Mills, Stevenage, GBN, UNITED KINGDOM;
 Stephen Swanson, Stevenage, GBN, UNITED KINGDOM;
 Andrew John Walker, Stevenage, GBN, UNITED KINGDOM;
 Mark Wilkinson, Stevenage, GBN, UNITED KINGDOM;
Power of Attorney: The patent practitioners associated with Customer Number 23347.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/EP03/03343 03/27/2003

Foreign Applications

 UNITED KINGDOM 0023902.0 09/29/2000
 UNITED KINGDOM 0107644.7 03/27/2001

Projected Publication Date: 08/25/2005

Non-Publication Request: No

Early Publication Request: No

BEST AVAILABLE COPY**Title**

Process for the preparation of morpholine derivatives and intermediates therefore

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15****GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
9 October 2003 (09.10.2003)

PCT

(10) International Publication Number
WO 03/082835 A1

(51) International Patent Classification: C07D 265/30

(21) International Application Number: PCT/GB03/03343

(22) International Filing Date: 27 March 2003 (27.03.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0207450.8 28 March 2002 (28.03.2002) GB

(71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HAYES, Martin, Alistair [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). MILLS, Gail [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). SWANSON, Stephen [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). WALKER, Andrew, John [GB/GB]; GlaxoSmithKline,

Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). WILKINSON, Mark [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB).



(74) Agent: GIDDINGS, Peter, John; GlaxoSmithKline, Corporate Intellectual Property (CN925.1), 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GF, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GI, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NI, SN, TD, TG).

[Continued on next page]

(54) Title: PROCESS FOR THE PREPARATION OF MORPHOLINE DERIVATIVES AND INTERMEDIATES THEREFORE



(57) Abstract: Processes for the preparation of a compound of formula (IIA)(I), or a salt thereof; wherein: Z represents a bond, CO, SO₂, CR¹⁰R⁷(CH₂)_n, (CH₂)_nCR¹⁰R⁷, CHR⁷(CH₂)_n, CHR⁷(CH₂)_nS, CHR⁷(CH₂)_nOCO, CHR⁷(CH₂)_nCO, COCHR⁷(CH₂)_n or SO₂CHR⁷(CH₂)_n; R⁶ represents C₁₋₆ alkyl, C₂₋₆ alkenyl, aryl, heteroaryl, aryl-C₂₋₆ alkenyl-, -CN or a group of formula -Y²-J¹; R⁷ represents hydrogen, C₁₋₄ alkyl, CONR⁸R⁹ or COOC₁₋₆ alkyl; and

b represent 1 or 2, such that a+b represents 2 or 3; n represents an integer from 0 to 4; M represents a C₃₋₈ cycloalkyl or C₃₋₈ cycloalkenyl group fused to a monocyclic aryl or monocyclic heteroaryl group; J¹ represents a moiety of formula (K); (II), wherein X¹ represents oxygen, NR¹¹ or sulphur, X² represents CH₂, oxygen, NR¹² or sulphur, m¹ represents an integer from 1 to 3 and m² represents an integer from 1 to 3, provided that m¹+m² is in the range from 3 to 5, also provided that when both X¹ and X² represent oxygen, NR¹¹, NR¹² or sulphur, m¹ and m² must both not equal less than 2, wherein (K) is optionally substituted by one or more (eg. 1 or 2) -Y¹-aryl, -Y¹-heteroaryl, -Y¹-CO-aryl, -COX₁₋₆ cycloalkyl, -Y¹-CO-heteroaryl, -C₁₋₆ alkyl, -Y¹-COOC₁₋₆ alkyl, -Y¹-COC₁₋₆ alkyl, -Y²-W, -Y¹-CO-W, -Y²-NR¹⁵R¹⁶, -Y²-CONR¹⁵R¹⁶, hydroxy, oxo, -Y¹-SO₂NR¹⁵R¹⁶, -Y²-SO₂C₁₋₆ alkyl, -Y²-SO₂aryl, -Y²-SC₁₋₆ heteroaryl, -Y²-NR¹⁵C₁₋₆ alkyl, -Y²-NR¹⁵SO₂C₁₋₆ alkyl, -Y¹-NR¹⁵CONR¹⁵R¹⁶, -Y¹-NR¹⁵COOR¹⁶ or -Y¹-COCONR¹⁵R¹⁶ groups, and is optionally fused to a monocyclic aryl or heteroaryl ring; R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³ and R¹⁴ independently represent hydrogen or C₁₋₆ alkyl; R¹⁵ and R¹⁶ independently represent hydrogen or C₁₋₆ alkyl or R¹⁵ and R¹⁶ together with the nitrogen atom to which they are attached may form a morpholine, piperidine or pyrrolidine ring; R¹⁷ and R¹⁸ independently represent hydrogen or C₁₋₆ alkyl; W represents a saturated or unsaturated, non-aromatic 5-7 membered ring containing between 1 and 3 heteroatoms selected from nitrogen, oxygen or sulphur, optionally substituted with one or more C₁₋₆ alkyl, halogen or hydroxy groups; Y¹, Y² and Y³ independently represent a bond or a group of formula -(CH₂)_nCR⁴R⁵(CH₂)_n- wherein R⁵ and R⁶ independently represent hydrogen or C₁₋₄ alkyl or R⁵ and R⁶ may together with the carbon atom to which they are attached form a C₃₋₈ cycloalkyl group, and p and q independently represent an integer from 0 to 5 wherein p+q is an integer from 0 to 5, and: k is 1 or 2; are disclosed.

WO 03/082835 A1